Xencor (XNCR) Non-Current Debt (2023 - 2026)
Xencor (XNCR) reported Non-Current Debt of $82.1 million for Q1 2026, down 19.36% year-over-year from $101.8 million in Q1 2025, and up 7.38% quarter-over-quarter from $76.5 million in Q4 2025.
Xencor (XNCR) Non-Current Debt (2023 - 2026) Analysis & Trends
Xencor (XNCR) has 4 years of Non-Current Debt data on file, last reported at $82.1 million in Q1 2026.
- Non-Current Debt for Q1 2026 came in at $82.1 million, down 19.36% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.1 million (down 19.36% YoY), and the FY2025 annual result was $76.5 million, down 33.59% from the prior year.
- Non-Current Debt climbed to $82.1 million in Q1 2026 per XNCR's latest filing, from $76.5 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $161.8 million in Q4 2023 and troughed at $76.5 million in Q4 2025.
- A 4-year average of $114.0 million and a median of $108.5 million in 2024 frame the typical range for Non-Current Debt.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt slumped 33.59% in 2025, then decreased 19.36% in 2026.
- A 4-year view of Non-Current Debt shows it stood at $161.8 million in 2023, then dropped by 28.81% to $115.2 million in 2024, then tumbled by 33.59% to $76.5 million in 2025, then gained by 7.38% to $82.1 million in 2026.
- Business Quant data shows XNCR's Non-Current Debt at $82.1 million in Q1 2026, $76.5 million in Q4 2025, and $87.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 82.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 82.12 Mn |
| Mar 31, 2026 | 82.12 Mn |
| Dec 31, 2025 | 76.48 Mn |
| Dec 31, 2025 | 76.48 Mn |
| Sep 30, 2025 | 87.78 Mn |
| Sep 30, 2025 | 87.78 Mn |
| Jun 30, 2025 | 94.74 Mn |
| Jun 30, 2025 | 94.74 Mn |
| Mar 31, 2025 | 101.84 Mn |
| Mar 31, 2025 | 101.84 Mn |
| Dec 31, 2024 | 115.16 Mn |
| Dec 31, 2024 | 115.16 Mn |
| Sep 30, 2024 | 128.34 Mn |
| Sep 30, 2024 | 128.34 Mn |
| Jun 30, 2024 | 140.83 Mn |
| Jun 30, 2024 | 140.83 Mn |
| Mar 31, 2024 | 150.90 Mn |
| Mar 31, 2024 | 150.90 Mn |
| Dec 31, 2023 | 161.77 Mn |
| Dec 31, 2023 | 161.77 Mn |